Mizuho Securities analyst Salim Syed maintained a Buy rating on Cytokinetics (NASDAQ:CYTK) on Wednesday, setting a price target of $26, which is approximately 8.88% above the present share price of $23.88.
Syed expects Cytokinetics to post earnings per share (EPS) of -$0.62 for the first quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Cytokinetics, with an average price target of $32.43.
The analysts price targets range from a high of $50 to a low of $24.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $6.72 million and a net profit of -$36.41 million. The company's market cap is $1.7 billion.
According to TipRanks.com, Mizuho Securities analyst Salim Syed is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -3.5% and a 47.94% success rate.
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.